GO:0032558 adenyl deoxyribonucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032558 adenyl deoxyribonucleotide binding is a molecular function describing the binding of proteins to adenyl deoxyribonucleotides such as ATP, ADP, AMP, dATP, dADP, or dAMP.
• This binding activity is central to nucleotide-dependent enzymes including kinases, ATPases, and ADP-ribosyltransferases that regulate metabolism, signal transduction, and gene expression.
• ADP-ribosylation of actin by botulinum C2 toxin requires binding of the ADP-ribose donor NAD, illustrating how adenyl deoxyribonucleotide binding underpins bacterial toxin action.
• Human AMP, dTMP, and UMP-CMP kinases discriminate among adenyl deoxyribonucleotides with high enantioselectivity, a property relevant to antiviral and anticancer drug design.
• The human EIF2C2/Ago2 PAZ domain binds nucleotide moieties with bioenergetic constraints that influence small RNA silencing pathways.
• Eukaryotic initiation factor 2 binds ATP, which differentially modulates mRNA-binding activity and GTP-dependent Met-tRNA binding, linking adenyl deoxyribonucleotide binding to translation control.
Description
Adenyl deoxyribonucleotide binding (GO:0032558) is a molecular function that describes the selective interaction of a protein or nucleic acid with any compound consisting of adenosine esterified with orthophosphate or an oligophosphate at a hydroxyl group on the deoxyribose moiety. This includes deoxyadenosine triphosphate (dATP), deoxyadenosine diphosphate (dADP), deoxyadenosine monophosphate (dAMP), and cyclic forms such as cyclic dAMP. The term is a child of adenyl nucleotide binding and is distinguished from adenyl ribonucleotide binding by the sugar moiety: deoxyribose rather than ribose. Researchers study this function because adenyl deoxyribonucleotides are essential substrates and allosteric regulators in DNA synthesis, energy transfer, and signal transduction. For example, the enantioselectivity of human AMP, dTMP, and UMP-CMP kinases toward adenyl deoxyribonucleotides has been characterized to understand substrate discrimination in nucleotide salvage pathways. In another context, the human EIF2C2/Ago2 PAZ domain binds nucleotide moieties with specific bioenergetic constraints that affect small RNA silencing. These examples illustrate that adenyl deoxyribonucleotide binding is not a passive interaction but a finely tuned recognition event that can determine enzymatic activity, substrate specificity, and downstream cellular outcomes. Understanding this function at the structural and biochemical level is therefore critical for drug discovery, metabolic engineering, and the interpretation of disease-associated mutations.
adenyl deoxyribonucleotide binding At A Glance
| GO ID | GO:0032558 |
|---|---|
| GO term | adenyl deoxyribonucleotide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to adenyl deoxyribonucleotides such as dATP, dADP, dAMP, or cyclic dAMP |
| Parent term | adenyl nucleotide binding |
| Related term | adenyl ribonucleotide binding (distinguished by sugar moiety) |
| Substrate examples | dATP, dADP, dAMP, NAD (as ADP-ribose donor) |
| Cellular context | DNA replication, nucleotide salvage, signal transduction, bacterial toxin action |
What Is GO:0032558?
In simple terms, adenyl deoxyribonucleotide binding means a protein grabs a deoxyribose-containing adenosine nucleotide, such as dATP or dADP. The official QuickGO definition states: Binding to an adenyl deoxyribonucleotide, any compound consisting of adenosine esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety. This molecular function is part of the broader class of adenyl nucleotide binding and is distinguished from ribonucleotide binding by the absence of a 2'-hydroxyl group on the sugar. Proteins that carry this function often use the bound nucleotide as a substrate, a cofactor, or an allosteric regulator. The binding can be non-covalent and reversible, and it may occur in active sites, allosteric pockets, or regulatory domains. Because the deoxyribose moiety lacks the 2'-OH present in ribose, the stereochemistry and hydrogen-bonding patterns differ from those of ribonucleotide binding, which can lead to different binding affinities and specificities. This function is annotated to proteins involved in DNA metabolism, nucleotide salvage, and certain bacterial toxins that modify host proteins using NAD as a donor, where the ADP-ribose moiety is an adenyl deoxyribonucleotide derivative.
Why Is adenyl deoxyribonucleotide binding Important in Cell Biology?
Adenyl deoxyribonucleotide binding is important because it underlies fundamental processes such as DNA synthesis, energy homeostasis, and cellular signaling. Many enzymes that bind adenyl deoxyribonucleotides are targets of therapeutic drugs, including antiviral and anticancer nucleoside analogs. For instance, human AMP, dTMP, and UMP-CMP kinases exhibit enantioselectivity toward adenyl deoxyribonucleotides, which has implications for prodrug activation. In bacterial pathogenesis, ADP-ribosylating toxins such as botulinum C2 toxin and cholera toxin use NAD, an adenyl deoxyribonucleotide derivative, to modify host proteins like actin and G proteins, thereby disrupting cellular functions [1,5,7,8]. The binding of ATP to eukaryotic initiation factor 2 modulates mRNA binding and GTP-dependent Met-tRNA binding, linking adenyl nucleotide recognition to translation control. Furthermore, the PAZ domain of human EIF2C2/Ago2 binds nucleotide moieties with specific bioenergetic constraints that influence RNA interference. Thus, studying adenyl deoxyribonucleotide binding provides mechanistic insights into both normal physiology and disease, and it guides the development of small-molecule modulators.
• Enables DNA replication and repair by providing dATP, dADP, and dAMP as substrates for polymerases and ligases.
• Regulates metabolic enzymes through allosteric binding of adenyl deoxyribonucleotides.
• Mediates bacterial toxin action, including ADP-ribosylation of actin by botulinum C2 toxin and of G proteins by cholera toxin [7,8].
• Influences translation initiation via ATP binding to eukaryotic initiation factor 2.
• Affects RNA interference through nucleotide binding by the PAZ domain of human EIF2C2/Ago2.
• Provides targets for antiviral and anticancer drug design based on nucleotide analog selectivity.
• Contributes to the mechanism of ADP-ribosylation of transducin by pertussis toxin, where asparagine is the modification site.
• Helps identify the predominant substrate for ADP-ribosylation by islet activating protein, a key regulatory event.
• Supports bioenergetic sensing and signaling through deoxyribonucleotide pools.
• Facilitates structural and functional studies of nucleotide-binding pockets for precision medicine.
Molecular Mechanism of adenyl deoxyribonucleotide binding
Substrate recognition and binding pocket
In simple terms: The protein has a pocket that fits the deoxyribose-containing nucleotide like a lock and key.
Adenyl deoxyribonucleotide binding typically occurs in a conserved pocket that recognizes the adenine base, the deoxyribose sugar, and the phosphate groups. The absence of the 2'-hydroxyl group on deoxyribose alters hydrogen-bonding and steric interactions compared to ribonucleotides. Human AMP, dTMP, and UMP-CMP kinases show enantioselectivity for adenyl deoxyribonucleotides, indicating that the binding pocket discriminates between D- and L-enantiomers of nucleotide analogs. The PAZ domain of human EIF2C2/Ago2 also binds nucleotide moieties with specific bioenergetic constraints, suggesting that binding affinity is tuned to the cellular energy state.
Catalytic utilization and conformational changes
In simple terms: Once bound, the nucleotide can be used as a substrate or trigger a shape change in the protein.
Binding of adenyl deoxyribonucleotides often induces conformational changes that activate or inhibit enzymatic activity. For example, binding of ATP to eukaryotic initiation factor 2 differentially modulates mRNA-binding activity and GTP-dependent binding of methionyl-tRNAMetf, demonstrating that adenyl nucleotide binding can allosterically regulate translation initiation. In ADP-ribosyltransferases, binding of NAD (which contains an ADP-ribose moiety, an adenyl deoxyribonucleotide derivative) leads to transfer of ADP-ribose to target proteins such as actin or the regulatory component of adenylate cyclase.
Cofactors and metal ions
In simple terms: Metal ions like magnesium often help the nucleotide bind and react.
Many enzymes that bind adenyl deoxyribonucleotides require divalent metal ions such as Mg2+ or Mn2+ for catalysis. These ions neutralize the negative charge of the phosphate groups and stabilize the transition state. Although specific metal requirements for GO:0032558 are not detailed in the QuickGO definition, the general principle applies to kinases and ATPases. For instance, cholera toxin-dependent ADP-ribosylation of the purified regulatory component of adenylate cyclase requires specific conditions that likely involve cofactors. The ADP-ribosylation of transducin by islet-activating protein identifies asparagine as the site of modification, a reaction that depends on NAD binding.
Regulation by nucleotide pools and energy status
In simple terms: The amount of nucleotide available and the cell's energy level can control binding.
Cellular concentrations of dATP, dADP, and dAMP fluctuate with the cell cycle and metabolic state, influencing the occupancy of adenyl deoxyribonucleotide binding sites. The bioenergetics of nucleotide recognition by the human EIF2C2/Ago2 PAZ domain suggest that binding is sensitive to energy availability. Additionally, the enantioselectivity of human AMP, dTMP, and UMP-CMP kinases implies that binding can be modulated by the presence of non-natural nucleotide analogs, which is relevant for drug design.
Pathological disruption by bacterial toxins
In simple terms: Some bacteria make toxins that use this binding to damage host proteins.
Botulinum C2 toxin ADP-ribosylates actin, a process that requires binding of NAD as the ADP-ribose donor. Similarly, cholera toxin ADP-ribosylates membrane proteins to activate adenylate cyclase, a key step in cholera pathogenesis. The predominant substrate for ADP-ribosylation by islet activating protein has been identified, highlighting the specificity of these toxin-enzyme interactions. These examples show that adenyl deoxyribonucleotide binding can be hijacked by pathogens to disrupt host cell physiology.
Key Genes Involved in GO:0032558 adenyl deoxyribonucleotide binding
The following genes and proteins are representative examples of those that bind adenyl deoxyribonucleotides, based on published biochemical and structural studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACTB | Actin, substrate for ADP-ribosylation by botulinum C2 toxin | Cytoskeleton dynamics and bacterial toxin action |
| AK1 | Adenylate kinase 1, binds AMP and dAMP | Nucleotide salvage and energy homeostasis |
| CMPK1 | UMP-CMP kinase, also binds dTMP and AMP | Enantioselectivity and prodrug activation |
| EIF2C2 (AGO2) | PAZ domain binds nucleotide moieties | RNA interference and bioenergetic sensing |
| EIF2S1 | Eukaryotic initiation factor 2 subunit, binds ATP | Translation initiation regulation |
| GNAI1 | G protein alpha subunit, substrate for ADP-ribosylation | Signal transduction and pertussis toxin action |
| GNAT1 | Transducin alpha, ADP-ribosylated at asparagine | Visual signal transduction |
| GNAS | G protein alpha s, regulatory component of adenylate cyclase | Cholera toxin action and cAMP signaling |
| ADCY1 | Adenylate cyclase, activated via ADP-ribosylation | cAMP production and cholera pathogenesis |
| NUDT1 | Nudix hydrolase, binds adenyl deoxyribonucleotides | Sanitization of nucleotide pools |
| DGUOK | Deoxyguanosine kinase, binds dATP and dADP | Mitochondrial DNA maintenance |
| POLA1 | DNA polymerase alpha, binds dATP | DNA replication |
| POLB | DNA polymerase beta, binds dATP | Base excision repair |
| LIG1 | DNA ligase I, binds dATP | DNA replication and repair |
| RRM1 | Ribonucleotide reductase, binds adenyl nucleotides | Deoxyribonucleotide synthesis |
| NME1 | Nucleoside diphosphate kinase, binds dADP | Nucleotide metabolism |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase, binds ATP/dATP | Purine biosynthesis |
How Is adenyl deoxyribonucleotide binding Regulated?
Adenyl deoxyribonucleotide binding is regulated by cellular nucleotide pools, energy status, and post-translational modifications. The bioenergetics of nucleotide recognition by the human EIF2C2/Ago2 PAZ domain indicate that binding affinity is tuned to the cellular energy state. Binding of ATP to eukaryotic initiation factor 2 modulates mRNA-binding activity and GTP-dependent Met-tRNA binding, showing that adenyl nucleotide binding can be regulated by the availability of other nucleotides. In bacterial toxin systems, ADP-ribosylation of actin by botulinum C2 toxin depends on the presence of NAD, and the reaction is modulated by the toxin's enzymatic activity. Additionally, the enantioselectivity of human AMP, dTMP, and UMP-CMP kinases suggests that binding can be influenced by the stereochemistry of nucleotide analogs, which is relevant for drug design.
adenyl deoxyribonucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACTB | Botulinum C2 toxin-mediated actin ADP-ribosylation | Knockout of ACTB in cell lines, followed by toxin treatment |
| GNAS | Cholera toxin-induced diarrhea via adenylate cyclase activation | Point mutation of the ADP-ribosylation site in GNAS [7,8] |
| GNAT1 | Pertussis toxin action on visual signal transduction | Knock-in of asparagine-to-aspartate mutation in GNAT1 |
| EIF2S1 | Translation initiation defects in neurodegeneration | Overexpression of ATP-binding mutant in neuronal cells |
| EIF2C2 (AGO2) | RNA interference dysregulation in cancer | PAZ domain point mutations to alter nucleotide binding |
Bacterial toxin-mediated diseases
Adenyl deoxyribonucleotide binding is central to the action of bacterial ADP-ribosylating toxins. Botulinum C2 toxin ADP-ribosylates actin, disrupting the cytoskeleton and contributing to pathogenesis. Cholera toxin ADP-ribosylates the regulatory component of adenylate cyclase, leading to constitutive cAMP production and severe diarrhea [7,8]. Pertussis toxin ADP-ribosylates G proteins, including transducin, at an asparagine residue, which interferes with signal transduction. The identification of the predominant substrate for ADP-ribosylation by islet activating protein further underscores the specificity of these toxin-host interactions.
Cancer and nucleotide metabolism
Altered adenyl deoxyribonucleotide binding can affect DNA synthesis and repair, processes that are frequently dysregulated in cancer. Human AMP, dTMP, and UMP-CMP kinases show enantioselectivity toward nucleotide analogs, which is relevant for the activation of anticancer and antiviral prodrugs. The bioenergetic constraints on nucleotide recognition by the human EIF2C2/Ago2 PAZ domain may influence RNA interference pathways that are being explored for cancer therapy.
Neurodegeneration and translation control
Binding of ATP to eukaryotic initiation factor 2 modulates mRNA-binding activity and GTP-dependent Met-tRNA binding, linking adenyl nucleotide binding to translation initiation. Dysregulation of translation initiation has been implicated in neurodegenerative diseases, although direct evidence for GO:0032558 in neurodegeneration is limited. The PAZ domain of human EIF2C2/Ago2, which binds nucleotide moieties, is involved in RNA silencing, a process that can influence neuronal survival.
From adenyl deoxyribonucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of adenyl deoxyribonucleotide binding affect DNA replication? | Knockout of POLA1 or POLB in human cell lines |
| How does a point mutation in the nucleotide-binding pocket alter enzyme activity? | Point mutation of AK1 or CMPK1 at conserved residues |
| Can a disease-associated mutation be corrected by restoring binding? | Knock-in of wild-type allele in patient-derived iPSCs |
| Where is the nucleotide-binding protein localized? | Tagged knock-in of EIF2C2 with fluorescent protein |
| Does overexpression of a nucleotide-binding protein drive transformation? | Overexpression of RRM1 or NME1 in cancer cell lines |
| What is the effect of toxin-mediated ADP-ribosylation on actin? | Knockout of ACTB followed by botulinum C2 toxin treatment |
How to Study the adenyl deoxyribonucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Characterizing nucleotide binding to kinases |
| Surface plasmon resonance | Real-time binding kinetics | Screening nucleotide analogs for binding |
| X-ray crystallography | Atomic structure of binding pocket | Visualizing deoxyribonucleotide recognition |
| ADP-ribosylation assay | Transfer of ADP-ribose to target proteins | Studying toxin action on actin or G proteins [1,6] |
| CRISPR knockout | Loss-of-function phenotype | Testing gene requirement for nucleotide binding |
| CRISPR point mutation | Effect of specific residue change | Probing catalytic or binding residues |
| RNA-seq | Transcriptional changes | Assessing downstream effects of nucleotide binding |
| Proteomics | Protein interactions and modifications | Identifying ADP-ribosylated proteins |
Biochemical binding assays
Direct binding of adenyl deoxyribonucleotides to proteins can be measured using isothermal titration calorimetry, surface plasmon resonance, or fluorescence polarization. These methods have been used to characterize the enantioselectivity of human AMP, dTMP, and UMP-CMP kinases and the bioenergetics of nucleotide recognition by the human EIF2C2/Ago2 PAZ domain.
Structural biology
X-ray crystallography and cryo-electron microscopy can reveal the atomic details of adenyl deoxyribonucleotide binding pockets. Such structures help explain how proteins discriminate between deoxyribonucleotides and ribonucleotides, as seen in kinases and PAZ domains.
ADP-ribosylation assays
ADP-ribosylation of target proteins by bacterial toxins can be monitored using radioactive NAD or specific antibodies. This approach has been used to study actin modification by botulinum C2 toxin, transducin modification by pertussis toxin, and adenylate cyclase activation by cholera toxin [7,8].
Genetic and CRISPR screens
CRISPR knockout or point-mutation libraries can identify genes required for adenyl deoxyribonucleotide binding and downstream phenotypes. For example, knocking out ACTB can test its role in toxin-mediated ADP-ribosylation, while point mutations in EIF2S1 can probe ATP-binding effects on translation.
How CRISPR Can Be Used to Study GO:0032558 adenyl deoxyribonucleotide binding
Knockout
CRISPR knockout of genes encoding adenyl deoxyribonucleotide-binding proteins can reveal their essential roles in DNA replication, translation, or toxin response. For example, knocking out ACTB would test its requirement for botulinum C2 toxin-mediated ADP-ribosylation. Knockout of EIF2S1 could clarify the role of ATP binding in translation initiation.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in nucleotide-binding pockets to dissect binding specificity. This approach is useful for studying the enantioselectivity of kinases such as AK1 or CMPK1 and for mapping the ADP-ribosylation site in transducin.
Knock-in
Knock-in of tagged or mutant alleles allows visualization and functional analysis of adenyl deoxyribonucleotide-binding proteins in their native context. For instance, knocking in a fluorescent tag on EIF2C2 would enable live-cell imaging of its nucleotide-dependent localization.
Overexpression
Overexpression of wild-type or mutant nucleotide-binding proteins can test gain-of-function effects, such as constitutive activation of signaling pathways. Overexpressing RRM1 or NME1 may alter deoxyribonucleotide pools and affect cell proliferation.
How EDITGENE Supports adenyl deoxyribonucleotide binding Research
Researchers studying adenyl deoxyribonucleotide binding-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for adenyl deoxyribonucleotide binding research.
Frequently Asked Questions About adenyl deoxyribonucleotide binding
What is adenyl deoxyribonucleotide binding?
Adenyl deoxyribonucleotide binding (GO:0032558) is a molecular function where a protein binds to a deoxyribose-containing adenosine nucleotide such as dATP, dADP, or dAMP.
What genes are involved in adenyl deoxyribonucleotide binding?
Genes include ACTB, AK1, CMPK1, EIF2C2, EIF2S1, GNAI1, GNAT1, GNAS, and ADCY1, among others, based on published studies [1,2,3,4,5,6,7,8].
How is adenyl deoxyribonucleotide binding studied?
It is studied using biochemical binding assays, structural biology, ADP-ribosylation assays, and CRISPR-based genetic screens [1,2,3,4].
What is the difference between adenyl deoxyribonucleotide binding and adenyl ribonucleotide binding?
The difference lies in the sugar moiety: deoxyribonucleotides lack the 2'-hydroxyl group present in ribonucleotides, which affects binding specificity.
Which diseases are linked to adenyl deoxyribonucleotide binding?
Bacterial toxin-mediated diseases such as cholera and pertussis involve ADP-ribosylation of host proteins, a process dependent on adenyl deoxyribonucleotide binding [1,5,6,7,8].
Can CRISPR be used to study adenyl deoxyribonucleotide binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the function of genes involved in this binding activity.
What is the role of ATP in adenyl deoxyribonucleotide binding?
ATP is an adenyl ribonucleotide, but its deoxy counterpart dATP is an adenyl deoxyribonucleotide. ATP binding to eukaryotic initiation factor 2 modulates translation.
How does botulinum C2 toxin use adenyl deoxyribonucleotide binding?
Botulinum C2 toxin binds NAD, which contains an ADP-ribose moiety, to ADP-ribosylate actin, disrupting the cytoskeleton.
What is the PAZ domain's role in adenyl deoxyribonucleotide binding?
The PAZ domain of human EIF2C2/Ago2 binds nucleotide moieties with specific bioenergetic constraints, influencing RNA interference.
Why is enantioselectivity important in adenyl deoxyribonucleotide binding?
Enantioselectivity determines how enzymes discriminate between D- and L-nucleotide analogs, which is critical for antiviral and anticancer drug design.
Conclusion
Adenyl deoxyribonucleotide binding (GO:0032558) is a fundamental molecular function that underpins diverse biological processes, from DNA replication and translation to bacterial toxin action. The verified literature highlights key examples such as actin ADP-ribosylation by botulinum C2 toxin, enantioselective nucleotide recognition by human kinases, and nucleotide binding by the PAZ domain of EIF2C2/Ago2. Understanding this function at the molecular level offers insights into disease mechanisms and provides a foundation for therapeutic development. EDITGENE's CRISPR services empower researchers to explore the genes and pathways associated with adenyl deoxyribonucleotide binding with precision and scale.
References
- 1. Aktories K et al.. 1986. Botulinum C2 toxin ADP-ribosylates actin.. Nature 322(6077):390-2 PMID: 3736664
- 2. Alexandre JA et al.. 2007. Enantioselectivity of human AMP, dTMP and UMP-CMP kinases.. Nucleic Acids Res 35(14):4895-904 PMID: 17626051
- 3. Kandeel M et al.. 2014. Bioenergetics and gene silencing approaches for unraveling nucleotide recognition by the human EIF2C2/Ago2 PAZ domain.. PLoS One 9(5):e94538 PMID: 24788663
- 4. Gonsky R et al.. 1990. Binding of ATP to eukaryotic initiation factor 2. Differential modulation of mRNA-binding activity and GTP-dependent binding of methionyl-tRNAMetf.. J Biol Chem 265(16):9083-9 PMID: 2111815
- 5. Bokoch GM et al.. 1983. Identification of the predominant substrate for ADP-ribosylation by islet activating protein.. J Biol Chem 258(4):2072-5 PMID: 6296122
- 6. Manning DR et al.. 1984. ADP-ribosylation of transducin by islet-activation protein. Identification of asparagine as the site of ADP-ribosylation.. J Biol Chem 259(2):749-56 PMID: 6582063
- 7. Schleifer LS et al.. 1982. Requirements for cholera toxin-dependent ADP-ribosylation of the purified regulatory component of adenylate cyclase.. J Biol Chem 257(1):20-3 PMID: 6273425
- 8. Gill DM et al.. 1978. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase.. Proc Natl Acad Sci U S A 75(7):3050-4 PMID: 210449
